MARKET

CLVS

CLVS

Clovis Oncology Inc
NASDAQ
1.300
+0.090
+7.44%
After Hours: 1.280 -0.02 -1.54% 16:05 10/04 EDT
OPEN
1.240
PREV CLOSE
1.210
HIGH
1.310
LOW
1.190
VOLUME
2.84M
TURNOVER
0
52 WEEK HIGH
4.760
52 WEEK LOW
0.5810
MARKET CAP
187.82M
P/E (TTM)
-0.6533
1D
5D
1M
3M
1Y
5Y
Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings
Benzinga · 1d ago
What Is Going on With Xperi (XPER) Stock Today?
Investor Place · 1d ago
Why Is Petrobras (PBR) Stock Up 12% Today?
Investor Place · 1d ago
Why Is Clovis Oncology (CLVS) Stock Up Today?
Investor Place · 1d ago
BRIEF-Triton3 Phase 3 Trial Of Rubraca Meets Primary Endpoint In Men With A Type of Prostate Cancer
BRIEF-Triton3 Phase 3 Trial Of Rubraca Meets Primary Endpoint In Men With A Type of Prostate Cancer
Reuters · 1d ago
Clovis Oncology Announces TRITON3 Phase 3 Trial Of Rubraca Achieves Primary Endpoint In Men With Metastatic Castration-Resistant Prostate Cancer With BRCA Or ATM Mutations
TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM
Benzinga · 1d ago
Clovis Oncology Says Confirmatory Prostate Cancer Study of Rubraca Meets Primary Endpoint
Clovis Oncology Says Confirmatory Prostate Cancer Study of Rubraca Meets Primary Endpoint
MT Newswires · 1d ago
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector stands at 3.54%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.  
Benzinga · 09/26 14:27
More
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.